Biodesix reported a quarterly loss of $0.81 per share, beating the Zacks Consensus Estimate for a $1.26 loss and improving from a $1.60 loss a year ago. The narrower-than-expected loss suggests better operating performance and is modestly positive for the stock. The report is likely to matter primarily to Biodesix shares rather than the broader market.
Biodesix reported a quarterly loss of $0.81 per share, beating the Zacks Consensus Estimate for a $1.26 loss and improving from a $1.60 loss a year ago. The narrower-than-expected loss suggests better operating performance and is modestly positive for the stock. The report is likely to matter primarily to Biodesix shares rather than the broader market.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
